Catalyst Pharmaceutical Partners, Inc. (CPRX) Reports Successful Completion Of Type B Breakthrough Therapy Meeting With FDA On Firdapse Tablets Development Program
1/6/2014 9:11:05 AM
CORAL GABLES, Fla., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective, approved medicines targeting orphan neuromuscular and neurological diseases, today announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) about Firdapse™ tablets (Amifampridine), its lead product being evaluated for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by